Teza Capital Management LLC Sells 86,911 Shares of Elanco Animal Health Incorporated $ELAN

Teza Capital Management LLC lowered its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 87.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,907 shares of the company’s stock after selling 86,911 shares during the period. Teza Capital Management LLC’s holdings in Elanco Animal Health were worth $136,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in ELAN. Allworth Financial LP grew its position in Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after purchasing an additional 2,090 shares in the last quarter. CoreCap Advisors LLC bought a new position in Elanco Animal Health in the fourth quarter valued at $29,000. NBC Securities Inc. bought a new position in Elanco Animal Health in the first quarter valued at $40,000. Parallel Advisors LLC grew its position in Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock valued at $41,000 after purchasing an additional 1,852 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock valued at $46,000 after purchasing an additional 1,740 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $18.79 on Wednesday. The company has a fifty day moving average price of $16.13 and a two-hundred day moving average price of $13.04. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The stock has a market cap of $9.34 billion, a P/E ratio of 21.85, a P/E/G ratio of 3.54 and a beta of 1.62. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $19.08.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.06. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. Elanco Animal Health’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on ELAN. Wall Street Zen raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Saturday, July 5th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 20th. Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. UBS Group increased their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, August 8th. Finally, Leerink Partners upgraded shares of Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.